Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 944-951

  Youn, HyeSook ^a   Jeong, Ji Cheon ^b   Jeong, Young Seok ^b   Kim, Eun Joo ^c   Um, Soo Jong ^a  

^a Sejong University   (South Korea)

^b Dongguk University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Apoptosis; Death receptor; Lung cancer; Nuclear factor kappaB pathway; Quercetin

Indexed keywords

CASPASE; CASPASE 10; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEATH RECEPTOR; DNA FRAGMENTATION FACTOR 45; FAS ANTIGEN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; PROTEIN P53; QUERCETIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN H460; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME REPRESSION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84878828237     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01004     Document Type: Article

References (31)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med., 359, 1367-1380 (2008).
2. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med., 13, 287-297 (2012).
3. Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin. Chest Med., 32, 839-851 (2011).
4. Paoletti L, Pastis NJ, Denlinger CE, Silvestri GA. A decade of advances in treatment of early-stage lung cancer. Clin. Chest Med., 32, 827-838 (2011).
5. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer, 18, 1-29 (1992).
6. Hertog MG. Epidemiological evidence on potential health properties of flavonoids. Proc. Nutr. Soc., 55 (1B), 385-397 (1996).
7. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front. Biosci., 9, 2714-2724 (2004).
8. Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr. Cancer, 50, 1-7 (2004).
9. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J. Med. Food, 8, 281-290 (2005).
10. Nishiumi S, Miyamoto S, Kawabata K, Ohnishi K, Mukai R, Murakami A, Ashida H, Terao J. Dietary flavonoids as cancer-preventive and therapeutic biofactors. Front Biosci (Schol Ed), 3, 1332-1362 (2011).
11. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. J. Natl. Cancer Inst., 92, 154-160 (2000).
12. Arts IC. A review of the epidemiological evidence on tea, flavonoids, and lung cancer. J. Nutr., 138, 1561S-1566S (2008).
13. Wätjen W, Michels G, Steffan B, Niering P, Chovolou Y, Kampkötter A, Tran-Thi QH, Proksch P, Kahl R. Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis. J. Nutr., 135, 525-531 (2005).
14. Vargas AJ, Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr. Rev., 68, 418-428 (2010).
15. Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm. Allergy Drug Targets, 9, 263-285 (2010).
16. Ishizawa K, Yoshizumi M, Kawai Y, Terao J, Kihira Y, Ikeda Y, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J. Pharmacol. Sci., 115, 466-470 (2011).
17. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol. Rep., 61, 67-75 (2009).
18. Ossola B, Kääriäinen TM, Männistö PT. The multiple faces of quercetin in neuroprotection. Expert Opin. Drug Saf., 8, 397-409 (2009).
19. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules, 15, 7792-7814 (2010).
20. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett., 269, 315-325 (2008).
21. Seufi AM, Ibrahim SS, Elmaghraby TK, Hafez EE. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J. Exp. Clin. Cancer Res., 28, 80-87 (2009).
22. Priyadarsini RV, Vinothini G, Murugan RS, Manikandan P, Nagini S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer, 63, 218-226 (2011).
23. Camargo CA, da Silva ME, da Silva RA, Justo GZ, Gomes-Marcondes MC, Aoyama H. Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem. Biophys. Res. Commun., 406, 638-642 (2011).
24. Mendoza EE, Burd R. Quercetin as a systemic chemopreventative agent: structural and functional mechanisms. Mini Rev. Med. Chem., 11, 1216-1221 (2011).
25. Djuric Z, Severson RK, Kato I. Association of dietary quercetin with reduced risk of proximal colon cancer. Nutr. Cancer, 64, 351-360 (2012).
26. Park UH, Jeong JC, Jang JS, Sung MR, Youn H, Lee SJ, Kim EJ, Um SJ. Negative regulation of adipogenesis by kaempferol, a component of Rhizoma Polygonati falcatum in 3T3-L1 cells. Biol. Pharm. Bull., 35, 1525-1533 (2012).
27. Schmid I, Uittenbogaart C, Jamieson BD. Live-cell assay for detection of apoptosis by dual-laser flow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nat. Protoc., 2, 187-190 (2007).
28. Lee HK, Park UH, Kim EJ, Um SJ. MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. EMBO J., 26, 3545-3557 (2007).
29. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer, 12, 121-132 (2012).
30. Dyson HJ, Komives EA. Role of disorder in IκB-NFκB interaction. IUBMB Life, 64, 499-505 (2012).
31. Hinz M, Arslan SÇ, Scheidereit C. It takes two to tango: IκBs, the multifunctional partners of NF-κB. Immunol. Rev., 246, 59-76 (2012).